NeXT Personal delivers industry-leading sensitivity to detect MRD and cancer recurrence at the earliest timepoints. The assay tracks and annotates individual variants over the whole evolution of a patient's trajectory in a single panel design. Variants tracked within NeXT Personal are derived from those detected in the tissue and include those known to be associated with cancer recurrence or therapy resistance.

Personalis selected GenomOncology to facilitate variant review, interpretation, and reporting for NeXT Personal. The GO Pathology Workbench streamlines variant analysis for all panels due to its intuitive workflow and extensive knowledge base of evidence, guideline-based therapies, and biomarker-based clinical trials, providing the insights needed for clinicians to guide patient decisions.

"The flexibility of the GO Pathology Workbench permits the efficient addition of new panels and alteration types, giving institutions the ability to continuously advance their solution or test offerings. By supporting MRD analysis with NeXT Personal, the GO Pathology Workbench aids Personalis in their case analysis by yielding the data required to identify disease progression for patients at an earlier stage of recurrence," said Sarah Dubay, Client Services.